This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Current Discounted Rates End In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Paul McCormac, , Ph.D.
SVP Technical Operations at LEXEO Therapeutics

Profile

Paul McCormac, PhD, joined LEXEO Therapeutics as SVP Technical Operations in March 2021. LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need. Prior to LEXEO, Dr. McCormac  was an Executive Director, Medicinal sciences category lead for Pfizer Rare Disease. He represented CMC/product development to Pfizer ‘s Rare Disease Business and Research Units with a major focus on Pfizer’s Gene Therapy CMC strategy. From 2008 to 2016 Paul was a product development leader for Pfizer’s manufacturing organization, leading large molecule products in late development and commercialization. Prior to joining Pfizer Paul was a director of process development for Avecia Biotechnology a leading contract manufacturer of oligonucleotide therapeutics.


Agenda Sessions

  • Delivering the Promise of Nucleic Acid Medicines: The Challenge of Scale Cost and Sustainability

    3:00pm